COMPANY Data
My FAVORITES

Movers and SHAKERS

Ticker | EYPT (Nasdaq) |
Current Price | $9.78 ↑ 0.18 |
Market Cap | 280.53M |
Volume | 65.86k |
52wk Range | $3.52 - $15.07 |
ADVANCED MARKET DATA |

Advanced Market Data
EyePoint Pharmaceuticals Inc. (EYPT)Overview
EyePoint Pharmaceuticals Inc is a US-based specialty pharmaceutical company which is engaged in developing sustained-release drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness. The company has developed three sustained-release products for the treatment of back-of-the-eye diseases. The lead product candidate is Durasert which is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye for three years from a single injection. The company's development program is focused primarily on utilizing two core technology platforms to deliver drugs and biologics to treat chronic diseases.
For further details see:
EyePoint Pharmaceuticals' (EYPT) CEO Nancy Lurker on Q4 2020 Results - Earnings Call TranscriptEyePoint Pharmaceuticals Inc. Corporate Filings
EyePoint Pharmaceuticals Inc. Corporate Events
EyePoint Pharmaceuticals Inc. Press Releases / News Feed
Channelchek
Not available
Channelchek
No reports available